First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease

Autores
Ramirez, Juan C.; Parrado, Rudy; Sulleiro, Elena; de la Barra, Anabelle; Rodriguez, Marcelo; Villarroel, Sandro; Irazu, Lucía; Alonso-Vega, Cristina; Alves, Fabiana; Curto, María A; Garcia, Lineth; Ortiz, Lourdes; Torrico, Faustino; Gascon, Joaquim; Flevaud, Laurence; Molina, Israel; Ribeiro, Isabela; Schijman, Alejandro G.
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Fil: Parrado, Rudy. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Sulleiro, Elena. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.
Fil: de la Barra, Anabelle. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Rodríguez, Marcelo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Villarroel, Sandro. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Irazu, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Alonso-Vega, Cristina. Drugs for Neglected Diseases initiative; Suiza.
Fil: Alves, Fabiana. Drugs for Neglected Diseases initiative; Suiza.
Fil: Curto, María A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Fil: García, Lineth. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Ortiz, Lourdes. Universidad Autónoma Juan Misael Saracho; Bolivia.
Fil: Torrico, Faustino. Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente; Bolivia.
Fil: Gascón, Joaquim. ISGlobal. Barcelona Centre for International Health Research. Hospital Clínic-Universitat de Barcelona; España.
Fil: Flevaud, Laurence. Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA); España.
Fil: Molina, Israel. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.
Fil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Suiza.
Fil: Schijman, Alejandro G. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Real-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD.
Fuente
PLoS One 2017; 12(11):e0188550
Materia
Enfermedad de Chagas
Humanos
Monitoreo Fisiológico
Nitroimidazoles
Reacción en Cadena en Tiempo Real de la Polimerasa
Triazoles
Tripanocidas
Nivel de accesibilidad
acceso abierto
Condiciones de uso
Repositorio
Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Institución
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
OAI Identificador
oai:sgc.anlis.gob.ar:123456789/1947

id SGCANLIS_e60dda56e5ed3bb507fc66ff2413f791
oai_identifier_str oai:sgc.anlis.gob.ar:123456789/1947
network_acronym_str SGCANLIS
repository_id_str a
network_name_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
spelling First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas diseaseRamirez, Juan C.Parrado, RudySulleiro, Elenade la Barra, AnabelleRodriguez, MarceloVillarroel, SandroIrazu, LucíaAlonso-Vega, CristinaAlves, FabianaCurto, María AGarcia, LinethOrtiz, LourdesTorrico, FaustinoGascon, JoaquimFlevaud, LaurenceMolina, IsraelRibeiro, IsabelaSchijman, Alejandro G.Enfermedad de ChagasHumanosMonitoreo FisiológicoNitroimidazolesReacción en Cadena en Tiempo Real de la PolimerasaTriazolesTripanocidasFil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: Parrado, Rudy. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.Fil: Sulleiro, Elena. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.Fil: de la Barra, Anabelle. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.Fil: Rodríguez, Marcelo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Villarroel, Sandro. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.Fil: Irazu, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Alonso-Vega, Cristina. Drugs for Neglected Diseases initiative; Suiza.Fil: Alves, Fabiana. Drugs for Neglected Diseases initiative; Suiza.Fil: Curto, María A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: García, Lineth. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.Fil: Ortiz, Lourdes. Universidad Autónoma Juan Misael Saracho; Bolivia.Fil: Torrico, Faustino. Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente; Bolivia.Fil: Gascón, Joaquim. ISGlobal. Barcelona Centre for International Health Research. Hospital Clínic-Universitat de Barcelona; España.Fil: Flevaud, Laurence. Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA); España.Fil: Molina, Israel. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.Fil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Suiza.Fil: Schijman, Alejandro G. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Real-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD.Public Library of Science2017-12-27info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://sgc.anlis.gob.ar/handle/123456789/194710.1371/journal.pone.0188550PLoS One 2017; 12(11):e0188550reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLIS#PLACEHOLDER_PARENT_METADATA_VALUE#datasetsPloS oneenginfo:eu-repo/semantics/openAccess2025-09-29T14:30:33Zoai:sgc.anlis.gob.ar:123456789/1947Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-29 14:30:33.521Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false
dc.title.none.fl_str_mv First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
title First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
spellingShingle First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
Ramirez, Juan C.
Enfermedad de Chagas
Humanos
Monitoreo Fisiológico
Nitroimidazoles
Reacción en Cadena en Tiempo Real de la Polimerasa
Triazoles
Tripanocidas
title_short First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
title_full First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
title_fullStr First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
title_full_unstemmed First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
title_sort First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
dc.creator.none.fl_str_mv Ramirez, Juan C.
Parrado, Rudy
Sulleiro, Elena
de la Barra, Anabelle
Rodriguez, Marcelo
Villarroel, Sandro
Irazu, Lucía
Alonso-Vega, Cristina
Alves, Fabiana
Curto, María A
Garcia, Lineth
Ortiz, Lourdes
Torrico, Faustino
Gascon, Joaquim
Flevaud, Laurence
Molina, Israel
Ribeiro, Isabela
Schijman, Alejandro G.
author Ramirez, Juan C.
author_facet Ramirez, Juan C.
Parrado, Rudy
Sulleiro, Elena
de la Barra, Anabelle
Rodriguez, Marcelo
Villarroel, Sandro
Irazu, Lucía
Alonso-Vega, Cristina
Alves, Fabiana
Curto, María A
Garcia, Lineth
Ortiz, Lourdes
Torrico, Faustino
Gascon, Joaquim
Flevaud, Laurence
Molina, Israel
Ribeiro, Isabela
Schijman, Alejandro G.
author_role author
author2 Parrado, Rudy
Sulleiro, Elena
de la Barra, Anabelle
Rodriguez, Marcelo
Villarroel, Sandro
Irazu, Lucía
Alonso-Vega, Cristina
Alves, Fabiana
Curto, María A
Garcia, Lineth
Ortiz, Lourdes
Torrico, Faustino
Gascon, Joaquim
Flevaud, Laurence
Molina, Israel
Ribeiro, Isabela
Schijman, Alejandro G.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Enfermedad de Chagas
Humanos
Monitoreo Fisiológico
Nitroimidazoles
Reacción en Cadena en Tiempo Real de la Polimerasa
Triazoles
Tripanocidas
topic Enfermedad de Chagas
Humanos
Monitoreo Fisiológico
Nitroimidazoles
Reacción en Cadena en Tiempo Real de la Polimerasa
Triazoles
Tripanocidas
dc.description.none.fl_txt_mv Fil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Fil: Parrado, Rudy. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Sulleiro, Elena. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.
Fil: de la Barra, Anabelle. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Rodríguez, Marcelo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Villarroel, Sandro. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Irazu, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Alonso-Vega, Cristina. Drugs for Neglected Diseases initiative; Suiza.
Fil: Alves, Fabiana. Drugs for Neglected Diseases initiative; Suiza.
Fil: Curto, María A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Fil: García, Lineth. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Ortiz, Lourdes. Universidad Autónoma Juan Misael Saracho; Bolivia.
Fil: Torrico, Faustino. Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente; Bolivia.
Fil: Gascón, Joaquim. ISGlobal. Barcelona Centre for International Health Research. Hospital Clínic-Universitat de Barcelona; España.
Fil: Flevaud, Laurence. Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA); España.
Fil: Molina, Israel. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.
Fil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Suiza.
Fil: Schijman, Alejandro G. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Real-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD.
description Fil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
publishDate 2017
dc.date.none.fl_str_mv 2017-12-27
dc.type.none.fl_str_mv info:ar-repo/semantics/articulo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sgc.anlis.gob.ar/handle/123456789/1947
10.1371/journal.pone.0188550
url http://sgc.anlis.gob.ar/handle/123456789/1947
identifier_str_mv 10.1371/journal.pone.0188550
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
datasets
PloS one
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv PLoS One 2017; 12(11):e0188550
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron:ANLIS
reponame_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
collection Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname_str Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron_str ANLIS
institution ANLIS
repository.name.fl_str_mv Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
repository.mail.fl_str_mv biblioteca@anlis.gov.ar
_version_ 1844621857995620352
score 12.559606